| Drug General Information |
| Drug ID |
D0R2SW
|
| Former ID |
DPR000048
|
| Drug Name |
FSA2
|
| Indication |
Fungal infections [ICD9: 110-118; ICD10:B35-B49]
|
Preclinical |
[1]
|
|---|
| Therapeutic Class |
Antifungal Agents
|
| Target and Pathway |
| Target(s) |
Fatty acid synthase |
Target Info |
Inhibitor |
[2]
|
|---|
|
BioCyc Pathway
|
Fatty acid biosynthesis initiation
|
|
Fatty acid elongation -- saturated
|
|
Palmitate biosynthesis
|
|
KEGG Pathway
|
Fatty acid biosynthesis
|
|
Metabolic pathways
|
|
Fatty acid metabolism
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
PathWhiz Pathway
|
Fatty Acid Biosynthesis
|
|
Reactome
|
ChREBP activates metabolic gene expression
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Fatty Acyl-CoA Biosynthesis
|
|
WikiPathways
|
Fatty Acid Biosynthesis
|
|
Nuclear Receptors Meta-Pathway
|
|
Liver X Receptor Pathway
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
SREBP signalling
|
|
Metabolism of water-soluble vitamins and cofactors
|
|
Integration of energy metabolism
|
|
Fatty acid, triacylglycerol, and ketone body metabolism
|
|
AMPK Signaling
|
| References |
| REF 1 | Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer. 2011 Sep;47(14):2221-9. |
|---|
| REF 2 | Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. Epub 2009 May 7. |
|---|
